WilmerHale Advises Intercept Pharmaceuticals in $460M Public Offering

WilmerHale Advises Intercept Pharmaceuticals in $460M Public Offering

Firm News

Related Solutions

Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
We guide clients through today’s ever-changing debt markets, representing them in a broad variety of debt deals that range from complex financial structures to traditional loan transactions.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, has announced the closing of an underwritten public offering of $460 million aggregate principal amount of 3.25% convertible senior notes due 2023. Intercept used a portion of the proceeds from the offering to fund the payment of capped call option transactions for the purpose of reducing potential dilution in connection with the notes.
 
The WilmerHale team was led by Partner Brian Johnson and included Counsel Chris Barnstable-Brown and Sarah Sellers and Associate Alicia Lee on corporate and securities matters, Partners Dino Wu and Jeannette Boot on derivatives matters, Partner John Sigel on credit matters, and Partner Julie Hogan Rodgers and Counsel Meghan Walsh on tax matters.

Read Intercept Pharmaceuticals' press release for more information. 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel